EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
12.15 - 13.45 Evidence-based prostate cancer therapies in cellular and animal
models
Amber Hall 1-2 - Level S2
Poster Session 68
Chairs: F.R. Santer, Innsbruck (AT)
T. Visakorpi, Tampere (FI)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
823 Transcriptional down-regulation of the androgen receptor by promoter G-quadruplex stabilisation; a
potential alternative treatment in castrate-resistant prostate cancer
T.J. Mitchell, A. Ramos-Montoya, M. Di Antonio, P. Murat, S. Ohnmacht, M. Micco, L. Fryer,
S. Balasubramanian, S. Neidle, D.E. Neal (Cambridge, London, United Kingdom)
* 824 Abiraterone is able to block AR activation induced by accumulating levels of precursor hormones resulting
from CYP17A1 inhibition
J.M. Moll, R.J. Van Soest, J. Kumagai, R. Graeser, I. Hickson, G.W. Jenster, W.M. Van Weerden (Rotterdam,
The Netherlands; Beerse, Belgium)
825 Modification of the integrins a2, a5 and b1 plays a particularly critical role in metastatic spread of RAD001resistant
prostate cancer cells
I. Tsaur, J. Makarevic, M. Kurosch, M. Reiter, G. Bartsch, A. Haferkamp, R. Blaheta (Frankfurt, Germany)
826 Targeting STAT3 in castration-resistant prostate cancer - identification of STAT3 as a direct target of the
fungal metabolite galiellalactone
N. Don-Doncow, M. Johansson, Z. Escobar, O. Sterner, A. Bjartell, R. Hellsten (Malmö, Lund, Sweden)
827 Novel anticancer effect of proteasome inhibitor on prostate cancer cells targeting prostate-specific
membrane antigen and androgen receptor
K. Kuroda, A. Horiguchi, T. Asano, S. Tasaki, J. Asakuma, A. Sato, K. Seguchi, K. Ito, T. Asano (Tokorozawa,
Saitama, Japan)
828 Antitumor activity of nanovectors encapsulating zoledronic acid (ZOL) in 3D prostate carcinoma spheroids
J. Schmidt, J. Kamradt, M. Stöckle, G. Derosa, A. Lombardi, M. Caraglia, G. Unteregger (Homburg, Germany;
Naples, Italy)
829 Improvement of efficacy of insulin-like growth-factor receptor (IGF)-targeting-therapies by co-targeting
insulin receptor A in prostate cancer
I. Heidegger, J. Kern, P. Massoner, H. Klocker (Innsbruck, Austria)
830 Resistance towards temsirolimus is counteracted by epigenetic intervention
J. Makarevic, I. Tsaur, E. Jüngel, A. Haferkamp, R. Blaheta (Frankfurt, Germany)
831 Mesenchymal stem cells carrying prodrug-activating enzymes inhibit tumor growth in immune-competent,
prostate cancer-bearing mice
A. Abrate, R. Buono, F Benigni, P. Hedlund, I.T.R. Cavarretta (Milan, Italy)
EAU Milan 2013
269
Monday